These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3480885)

  • 1. Decrease of caffeine elimination in man during co-administration of 4-quinolones.
    Stille W; Harder S; Mieke S; Beer C; Shah PM; Frech K; Staib AH
    J Antimicrob Chemother; 1987 Nov; 20(5):729-34. PubMed ID: 3480885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between quinolones and caffeine.
    Staib AH; Stille W; Dietlein G; Shah PM; Harder S; Mieke S; Beer C
    Drugs; 1987; 34 Suppl 1():170-4. PubMed ID: 3481318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
    Wise R; Griggs D; Andrews JM
    Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gyrase-inhibitors impair caffeine elimination in man.
    Staib AH; Harder S; Mieke S; Beer C; Stille W; Shah P
    Methods Find Exp Clin Pharmacol; 1987 Mar; 9(3):193-8. PubMed ID: 3037212
    [No Abstract]   [Full Text] [Related]  

  • 5. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H; Quentin C; de Barbeyrac B; Bebear C
    Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations.
    Harder S; Fuhr U; Staib AH; Wolff T
    Am J Med; 1989 Nov; 87(5A):89S-91S. PubMed ID: 2589393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-quinolones inhibit biotransformation of caffeine.
    Harder S; Staib AH; Beer C; Papenburg A; Stille W; Shah PM
    Eur J Clin Pharmacol; 1988; 35(6):651-6. PubMed ID: 2853056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1985 May; 15(5):551-8. PubMed ID: 3159712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics of new quinolones.
    Lode H; Höffken G; Prinzing C; Glatzel P; Wiley R; Olschewski P; Sievers B; Reimnitz D; Borner K; Koeppe P
    Drugs; 1987; 34 Suppl 1():21-5. PubMed ID: 3481323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
    Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
    Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    Infection; 1986; 14 Suppl 3():S196-202. PubMed ID: 3463542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine.
    Mahr G; Sörgel F; Granneman GR; Kinzig M; Muth P; Patterson K; Fuhr U; Nickel P; Stephan U
    Clin Pharmacokinet; 1992; 22 Suppl 1():90-7. PubMed ID: 1319876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of effect of ofloxacin on theophylline pharmacokinetics in rats.
    Okazaki O; Miyazaki K; Tachizawa H
    Chemotherapy; 1987; 33(6):402-11. PubMed ID: 3480792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition.
    Barnett G; Segura J; de la Torre R; Carbó M
    Eur J Clin Pharmacol; 1990; 39(1):63-9. PubMed ID: 2177401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparative pharmacokinetics of five quinolones.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
    Smith JT
    Scand J Infect Dis Suppl; 1986; 49():115-23. PubMed ID: 3547618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinolones.
    Shah PM
    Prog Drug Res; 1987; 31():243-56. PubMed ID: 3326031
    [No Abstract]   [Full Text] [Related]  

  • 19. In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.
    Berlin OG; Young LS; Bruckner DA
    J Antimicrob Chemother; 1987 May; 19(5):611-5. PubMed ID: 3112095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora.
    Edlund C; Nord CE
    Infection; 1988; 16(1):8-12. PubMed ID: 3283041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.